A XM não fornece serviços a residentes nos Estados Unidos da América.

Chip stocks, megacaps steer S&P 500, Nasdaq to record highs



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Chip stocks, megacaps steer S&P 500, Nasdaq to record highs</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.

S&P 500 notches 35th record closing high this year

Lilly up after data shows Mounjaro more efficient than Wegovy

Indexes: Dow down 0.38%, S&P up 0.21%, Nasdaq up 0.47%

Updated at 10:05 a.m. ET

By Lisa Pauline Mattackal and Ankika Biswas

July 9 (Reuters) - The S&P 500 and the Nasdaq hit record highs on Tuesday, powered by semiconductors andmegacaps, as Congress heard testimony from Federal Reserve Chair Jerome Powell, who said more "good" economic data would strengthen the case for interest-rate cuts.

AI-chip favorite Nvidia NVDA.O jumped 4%, while Applied Materials AMAT.O and Micron Technology MU.O gained 2% and 3%, respectively, steering the Philadelphia SE Semiconductor index .SOX to a record high.

The S&P 500 Information Technology Index .SPLRCT also hit an all-time high, along with megacaps including Alphabet GOOGL.O and Apple AAPL.O, while Meta Platforms META.O and Amazon.com AMZN.O rose0.9% and 0.3%, respectively.

Monday markedthe 35th instance of the S&P 500setting a fresh closing record this year, as sharp gains in AI-linked and other tech shares kept equity sentiment bright, offsetting the uncertainty around the Fed'srate-cut path.

However, the Dow Jones .DJI underperformed, with a 2% fall in Salesforce CRM.N being the biggest drag on the blue-chip index.

Meanwhile, in his Congressional testimony, Powell said that while inflation "remains above" the 2% soft-landing target, it has been improving in recent months and "more good data would strengthen" the case for rate cuts.

"It does sound like Powell is just looking for a few more months of decent inflation data in order to have the confidence to start cutting, so that could put a September rate cut in play," said Brian Jacobsen, chief economist at Annex Wealth Management.

The last set of economicprojections from the central bank's policymakers showed anexpectation of just one rate cut this year. But markets have stuck to pricing in 50 basis points of easing, seeing a nearly 72% chance for a 25 bps cut at the Fed's September meeting, according to CME's FedWatch.

Those bets were at under50% a month ago.

Crucial inflation data is also due this week, including Thursday'sconsumer price index and the producerprice index reading on Friday.

Investors also awaitthe start of the second-quarter corporate earnings season this week, with big banks due to report on Friday.

Analysts, on average, see S&P 500 companies increasing their aggregate earnings per share by 10.1% in the second quarter, up from an 8.2% increase in the first quarter, according to LSEG I/B/E/S data.

At 10:05 a.m. ET, the Dow Jones Industrial Average .DJI was down 147.89 points, or 0.38%, at 39,196.90, the S&P 500 .SPX was up 11.96 points, or 0.21%, at 5,584.81, and the Nasdaq Composite .IXIC was up 86.31 points, or 0.47%, at 18,490.05.

Among single movers, Tempus AI TEM.O jumped7.5% after multiple brokerages including J.P.Morgan and Morgan Stanley initiated coverage of the stock with bullish ratings.

Eli Lilly <LLY.N> edgedup 0.6% aftera data analysis report showed its treatment Mounjaro leads to faster and greater weight loss than Novo Nordisk's obesity drug, Wegovy.

CVS Health CVS.N and UnitedHealth Group UNH.N fell0.9% and 0.4%, respectively, after the U.S. Federal Trade Commission said a handful of pharmacy benefit managersexercized an outsized influence over prescription drug prices.

Declining issues outnumbered advancers for a 1.51-to-1 ratio on the NYSE, andfor a 1.31-to-1 ratio on the Nasdaq.

The S&P index recorded 19 new 52-week highs and ninenew lows, while the Nasdaq recorded 38 new highs and 74 new lows.



Reporting by Lisa Mattackal and Ankika Biswas in Bengaluru; Editing by Pooja Desai

</body></html>

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.